Basic Information
LONQUEX SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 6MG/0.6ML
INJECTION, SOLUTION
Regulatory Information
SIN16019P
September 25, 2020
Prescription Only
Therapeutic
SUBCUTANEOUS
August 10, 2023
June 3, 2025
XL03AA14
Company Information
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Active Ingredients
Strength: 6.00 mg/0.6ml
Detailed Information
Contraindications
**4.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.
Indication Information
**4.1 Therapeutic indications** Lonquex is indicated in adults for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).